Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00083434 · ClinicalTrials.gov registry record · Phase 3
Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy
A Phase 3 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Terminated
- Registry status
- Phase 3
- Development phase
NCT00083434: Clinical Trial Phase 3 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
NCT00083434 is a Phase 3 study that was terminated before completion, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00083434, a Phase 3 study, was terminated before completion, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- TERMINATED
- Registry status
- Phase 3
- Development phase
Study Summary
The purpose of this study is to examine the effectiveness of epoetin alfa in treating anemia in patients who have cancer or who no longer have any signs of the cancer, but remain anemic as a result of their treatment.
Interventions
- DRUG Epoetin alfa
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-02 |
| Est. Completion | 2004-10 |
| Phase | Phase 3 |
Why NCT00083434 stopped before completion
NCT00083434 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Epoetin alfa is the first listed.
NCT00083434 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00083434 about?
NCT00083434 is a clinical study titled "Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy". The purpose of this study is to examine the effectiveness of epoetin alfa in treating anemia in patients who have cancer or who no longer have any signs of the cancer, but remain anemic as a result of their treatment.
What is the current status of trial NCT00083434?
This trial is currently terminated. It is a Phase 3 study. The study started on 2004-02. Estimated completion is 2004-10.
What interventions are being tested in trial NCT00083434?
The interventions under investigation include: Epoetin alfa (DRUG).
Who is sponsoring clinical trial NCT00083434?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia